Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases-Focus on Epigenetic Mechanisms
Overview
Affiliations
The most common malignant gynecologic diseases are cervical, uterine, ovarian, vaginal, and vulvar cancer. Among them, ovarian cancer causes more deaths than any other cancer of the female reproductive system. A great number of women suffer from endometriosis, uterine fibroids (UFs), adenomyosis, dysmenorrhea, and polycystic ovary syndrome (PCOS), which are widespread benign health problems causing troublesome and painful symptoms and significantly impairing the quality of life of affected women, and they are some of the main causes of infertility. In addition to the available surgical and pharmacological options, the effects of supporting standard treatment with naturally occurring compounds, mainly polyphenols, are being studied. Catechins are responsible for the majority of potential health benefits attributed to green tea consumption. Epigallocatechin gallate (EGCG) is considered a non-toxic, natural compound with potential anticancer properties. Antioxidant action is its most common function, but attention is also drawn to its participation in cell division inhibition, apoptosis stimulation and epigenetic regulation. In this narrative review, we describe the role of EGCG consumption in preventing the development of benign reproductive disorders such as UF, endometriosis, and PCOS, as well as malignant gynecologic conditions. We discuss possible epigenetic mechanisms that may be related to the action of EGCG.
Role of Epigallocatechin Gallate in Selected Malignant Neoplasms in Women.
Markowska A, Antoszczak M, Markowska J, Huczynski A Nutrients. 2025; 17(2).
PMID: 39861342 PMC: 11767294. DOI: 10.3390/nu17020212.
Long Y, Shi H, Ye J, Qi X Antioxidants (Basel). 2025; 14(1).
PMID: 39857448 PMC: 11762571. DOI: 10.3390/antiox14010114.
Research Advances in Adenomyosis-Related Signaling Pathways and Promising Targets.
Zhang H, Li C, Li W, Xin W, Qin T Biomolecules. 2024; 14(11).
PMID: 39595579 PMC: 11591984. DOI: 10.3390/biom14111402.
Tsai Y, Tsai C, Yang J, Juan Y, Shih H, Bau D In Vivo. 2024; 38(6):2617-2628.
PMID: 39477405 PMC: 11535936. DOI: 10.21873/invivo.13738.
Research progress and applications of epigenetic biomarkers in cancer.
Gao J, Shi W, Wang J, Guan C, Dong Q, Sheng J Front Pharmacol. 2024; 15:1308309.
PMID: 38681199 PMC: 11048075. DOI: 10.3389/fphar.2024.1308309.